Vall d'Hebron Institute of Oncology (VHIO) is a center of biomedical research with scientists and physicians working together at the nexus of basic science and clinical research. Its main purpose is to promote and develop research excellence relating to oncological diseases. VHIO also pursues to make contributions to the development of new and better therapies for the treatment of cancer.
Subscribe to rss feed
Initial findings of the phase III KEYNOTE-811 trial of pembrolizumab plus trastuzumab and chemotherapy—first presented at ASCO 2021—have led to the subsequent FDA approval of this combination for the first-line treatment ...
Dec 15, 2021
0
41
During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...
Sep 20, 2021
0
3
Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics ...
Mar 8, 2021
0
29
Immunotherapy continues to show exciting promise in more effectively combating several tumor types. Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors. It is thought ...
Feb 23, 2021
0
41
Building on previous research 1—3 led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published ...
Oct 27, 2020
0
22
In today's current era of precision medicine against cancer, research is successfully potentiating and personalizing immunotherapy to unleash the power of the immune system in a greater number of patients to attack disease. ...
Oct 17, 2019
0
4
With an estimated 570,000 cases and 311,000 deaths in 2018 worldwide, cervical cancer currently ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. Furthermore, patients ...
Sep 30, 2019
0
2
Results from a study spearhead by researchers at the Vall d´Hebron Institute of Oncology (VHIO), show that the blockade of the multi-functional cytokine LIF induces tumor-infiltrating T cells to target and eliminate cancer. ...
Jun 11, 2019
0
54
Cutting-edge sequencing technology has revolutionized cancer diagnosis and since identified several so-called cancer driver genomic aberrations. This has led to the development of an extensive and powerful arsenal of anti-cancer ...
Mar 20, 2019
0
27
Not so long ago, immunotherapy against cancer was positioned as an emerging or even promising treatment, but not one with a proven track record. Today however, novel immunotherapeutics across different tumor types, either ...
Oct 3, 2018
0
128
